GSK PLC - EC approval of Shingrix PFS
Issued: 7th
GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission
· Prefilled syringe offers healthcare professionals a convenient administration option
· New presentation will begin rolling out across EU countries in 2026
· Shingles affects approximately 1.7 million people in
GSK plc (LSE/NYSE: GSK) today announced the European Commission's (EC) approval of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) in a prefilled syringe. The current vaccine presentation comprises two vials, one with a lyophilised powder antigen and another with a liquid adjuvant. The lyophilised powder antigen requires reconstitution, where the suspension in the adjuvant vial is withdrawn and injected into the antigen vial. The new prefilled syringe simplifies the vaccine administration process for healthcare professionals by removing the need to undertake these steps prior to administration.
This approval is based on data confirming technical comparability between the prefilled syringe and the existing vaccine presentation.[4] The new presentation does not involve a change in indication or dosing.
About shingles
Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox.2 Globally, up to 1 in 3 adults will develop shingles in their lifetime.2,[5],[6],[7] Over 90% of adults have the VZV dormant in their nervous system, waiting to reactivate.2,[8],[9],[10] In addition to advancing age, chronic conditions like cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, asthma, and diabetes are all linked to higher risk of shingles.2,3
Shingles typically presents as a rash, with painful blisters across the chest, abdomen or face.8 Following the rash, up to 30% of people experience post-herpetic neuralgia (PHN),[11] a long-lasting nerve pain that can last weeks or months and can occasionally persist for several years.2
About Shingrix (Recombinant Zoster Vaccine or RZV)
Shingrix combines an antigen, glycoprotein E, with an adjuvant system, AS01B, and may help overcome the natural age-related decline in responses to immunisation that contributes to the challenge of protecting adults aged 50 and over from shingles.[12],[13] RZV is not indicated to prevent primary varicella infection (chickenpox). The use of RZV should be in accordance with official recommendations and local product label.
GSK's shingles vaccine has been approved in the European Union for the prevention of herpes zoster (HZ) and PHN in adults aged 50 years or older since 2018; and in adults 18 years or older at increased risk of HZ, since 2020.
Please refer to the Product Information (PI) for important dosage, administration, and safety information in
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
|
GSK enquiries |
|
|
|
|
Media: |
|
+44 (0) 20 8047 5502 |
( |
|
|
|
+44 (0) 20 8047 5502 |
( |
|
|
|
+1 202 603 5003 |
( |
|
|
|
+1 202 302 4595 |
( |
|
|
|
+1 540 742 3391 |
( |
|
|
|
|
|
|
Investor Relations: |
Constantin Fest |
+44 (0) 7831 826525 |
( |
|
|
|
+44 (0) 20 8047 2406 |
( |
|
|
|
+44 (0) 7990 339653 |
( |
|
|
|
+44 (0) 7796 707505 |
( |
|
|
|
+44 (0) 7824 525779 |
( |
|
|
|
+1 215 751 7002 |
( |
|
|
|
+1 215 751 3126 |
( |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q3 Results for 2025.
Registered in
No. 3888792
Registered Office:
WC1A 1DG
References
[1] Pinchinat et al. Similar herpes zoster incidence across
[2] Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
[3] Steinmann et al. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns. Infection. 2024;52(3):1009-1026. doi: 10.1007/s15010-023-02156-y. REF-224255.
[4] GSK. Data on file.
[5] Australian Institute of Health and Welfare. Shingles in
[6] Lee C, et al. Lifetime risk of herpes zoster in the population of
[7] Curran D, et al. Meta-Regression of Herpes Zoster Incidence Worldwide. Infect Dis Ther. 2022;11(1):389-403.
[8] Mueller, N.H., et al. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurologic clinics. 2008;26(3):675-97.
[9] Johnson, R.W., et al. Herpes zoster epidemiology, management, and disease and economic burden in
[10] Bricout, H., et al. Herpes zoster-associated mortality in
[11] Kawai, K., et al. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ open. 2014;4(6).
[12] Cunningham, AL, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. New England Journal of Medicine. 2016;375(11):1019-32.
[13] The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon® adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc. (NASDAQ: AGEN), MPL and liposomes.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE